ZA202304534B - Use of therapeutic enzyme fusion protein for preventing and treating kidney disease caused or accompanied by fabry's disease - Google Patents

Use of therapeutic enzyme fusion protein for preventing and treating kidney disease caused or accompanied by fabry's disease

Info

Publication number
ZA202304534B
ZA202304534B ZA2023/04534A ZA202304534A ZA202304534B ZA 202304534 B ZA202304534 B ZA 202304534B ZA 2023/04534 A ZA2023/04534 A ZA 2023/04534A ZA 202304534 A ZA202304534 A ZA 202304534A ZA 202304534 B ZA202304534 B ZA 202304534B
Authority
ZA
South Africa
Prior art keywords
fabry
accompanied
fusion protein
preventing
disease
Prior art date
Application number
ZA2023/04534A
Other languages
English (en)
Inventor
Jae Hyuk Choi
Jin Young Kim
Cho Rong Park
Sang Yun Kim
Jeong A Kim
Doo Seo Jang
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of ZA202304534B publication Critical patent/ZA202304534B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
ZA2023/04534A 2020-11-13 2023-04-19 Use of therapeutic enzyme fusion protein for preventing and treating kidney disease caused or accompanied by fabry's disease ZA202304534B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200152247 2020-11-13
PCT/KR2021/016630 WO2022103221A1 (ko) 2020-11-13 2021-11-15 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도

Publications (1)

Publication Number Publication Date
ZA202304534B true ZA202304534B (en) 2024-10-30

Family

ID=81602509

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/04534A ZA202304534B (en) 2020-11-13 2023-04-19 Use of therapeutic enzyme fusion protein for preventing and treating kidney disease caused or accompanied by fabry's disease

Country Status (12)

Country Link
US (1) US20230405093A1 (cg-RX-API-DMAC7.html)
EP (1) EP4245311A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023549323A (cg-RX-API-DMAC7.html)
KR (1) KR20220065719A (cg-RX-API-DMAC7.html)
CN (1) CN116419760A (cg-RX-API-DMAC7.html)
AU (1) AU2021378707A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196258A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006437A2 (cg-RX-API-DMAC7.html)
IL (1) IL302858A (cg-RX-API-DMAC7.html)
MX (1) MX2023005580A (cg-RX-API-DMAC7.html)
WO (1) WO2022103221A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304534B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121793950A (zh) * 2023-09-14 2026-04-03 株式会社绿十字 新的含有α-半乳糖苷酶A融合蛋白的冻干制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
PT2542257T (pt) * 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
DK2865751T3 (en) * 2010-03-02 2017-01-09 Protalix Ltd Stabilized alpha-galactosidase and uses thereof
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
US12194079B2 (en) * 2017-01-05 2025-01-14 Protalix Ltd. Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase
US20200157172A1 (en) * 2017-07-07 2020-05-21 HANMl PHARM. CO., LTD. Novel therapeutic enzyme fusion protein and use thereof
FR3069340A1 (fr) * 2017-07-21 2019-01-25 Arkema France Procede de controle de l'orientation des nano-domaines d'un copolymere a blocs
EP3708661A4 (en) * 2017-12-22 2021-12-01 Hanmi Pharm. Co., Ltd. THERAPEUTIC ENZYMFUSION PROTEIN WITH A NEW STRUCTURE AND ITS USE

Also Published As

Publication number Publication date
JP2023549323A (ja) 2023-11-24
WO2022103221A1 (ko) 2022-05-19
CN116419760A (zh) 2023-07-11
CA3196258A1 (en) 2022-05-19
US20230405093A1 (en) 2023-12-21
MX2023005580A (es) 2023-05-29
AU2021378707A1 (en) 2023-06-01
IL302858A (en) 2023-07-01
CO2023006437A2 (es) 2023-06-09
AU2021378707A9 (en) 2024-07-11
EP4245311A4 (en) 2024-10-30
KR20220065719A (ko) 2022-05-20
EP4245311A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
PH12021550115A1 (en) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
WO2021252538A3 (en) Advantageous benzofuran compositions for mental disorders or enhancement
SA520411662B1 (ar) بروتينات التحام تشتمل على إنزيمات علاج بديل للإنزيم
WO2018112446A3 (en) Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease
PH12022551598A1 (en) Progranulin variants
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
MX2020008663A (es) Anticuerpos anti-angiopoyetina-2 y usos de los mismos.
EA200400518A1 (ru) Способы лечения глазных неоваскулярных заболеваний
MX2023004170A (es) Compuestos y oligonucleótidos derivados de n-acetilgalactosamina (galnac).
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
WO2007078845A3 (en) Systems and methods applying reversed sequence pressure to control edema flow
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
WO2000062790A3 (en) Soluble tumor necrosis factor receptor treatment of medical disorders
DE60133030D1 (de) Erung von gelenkschmerzen und steifheit
WO2020142740A8 (en) Treatment of sjogren's disease with nuclease fusion proteins
WO2022015573A3 (en) Sars-cov-2 antigen-binding proteins and uses thereof
EA200300560A1 (ru) Улучшенный способ лечения
MX2022010207A (es) Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o andamiaje no ig anti-adm para usarse en terapia o prevencion de choque.
WO2020102740A3 (en) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
MX2023005580A (es) Uso de una proteina de fusion enzimatica terapeutica en la prevencion y el tratamiento de enfermedades renales provocadas por o acompa?adas de la enfermedad de fabry.
ZA202110285B (en) Antibodies and methods of use
WO2022090469A3 (en) Ace2 fusion proteins and uses thereof
WO2004108885A3 (en) Fc chimeric proteins with anti-hiv drugs
MX2022003820A (es) Metodos de tratamiento para modificar la hermodinamica.
WO2021151043A3 (en) Methods and compositions for treating and preventing viral infection